What were the design, patient eligibility criteria, interventions, outcomes, and clinical implications of the ISCHEMIA trial?

The ISCHEMIA Trial: Design, Findings, and Clinical Implications

The ISCHEMIA (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches) trial demonstrated that in patients with stable coronary artery disease and moderate-to-severe ischemia, an initial invasive strategy (angiography followed by revascularization) did not reduce death or major cardiovascular events compared to optimal medical therapy alone over 3.2 years of follow-up, though it did provide superior angina relief in symptomatic patients. 1

Trial Design and Patient Population

The ISCHEMIA trial randomized 5,179 patients with stable coronary disease and site-determined moderate-to-severe ischemia on stress testing to either:

• Invasive strategy: Routine cardiac catheterization followed by revascularization (PCI or CABG) when feasible
• Conservative strategy: Optimal medical therapy (OMT) with catheterization reserved only for failure of medical management 2

Key Eligibility Criteria

Included patients had:

• Stable ischemic heart disease with moderate or severe ischemia on stress testing
• Obstructive coronary artery disease confirmed on blinded coronary CT angiography (in most patients with normal renal function)

Critical exclusions were:

• Left main stenosis >50%
• Left ventricular ejection fraction <35%
• eGFR <30 mL/min
• Recent myocardial infarction
• Unacceptable angina at baseline despite medical therapy 2

These exclusions are crucial because they define a specific population—the trial does not apply to patients with left main disease, severe LV dysfunction, or severe symptoms refractory to medical therapy, who likely benefit from revascularization based on other evidence 3.

Primary and Secondary Outcomes

Primary Endpoint

The composite of cardiovascular death, nonfatal MI, hospitalization for unstable angina, hospitalization for heart failure, or resuscitated cardiac arrest showed no significant difference between invasive and conservative strategies at median 3.3 years follow-up 1.

Key Secondary Findings

Mortality: No difference in all-cause mortality or cardiovascular death between strategies 1

Myocardial Infarction: The invasive strategy was associated with significantly lower rates of spontaneous MI during follow-up, though this was offset by periprocedural MIs 3, 4

Angina Relief: This is where the invasive strategy showed clear benefit:

• Patients with daily, weekly, or monthly angina experienced prompt and durable improvement in symptoms when randomized to invasive versus conservative management 1
• The ORBITA 2 trial corroborated this, showing patients with stable angina and objective ischemia had lower angina symptom scores following PCI 3
• Asymptomatic patients derived no benefit from invasive management 1

Relationship Between Ischemia Severity, CAD Severity, and Outcomes

A critical post-hoc analysis revealed important nuances 5:

Ischemia severity alone did not predict outcomes: Neither moderate nor severe ischemia was associated with increased mortality compared to mild/no ischemia after adjusting for CAD severity (HR for severe ischemia 0.83,95% CI 0.57-1.21) 5

CAD severity was the key prognostic factor: More severe anatomic disease (by modified Duke Prognostic Index) was associated with increased death (HR 2.72 for most vs least severe CAD) and MI (HR 3.78) 5

Treatment effect by CAD severity: In the most severe CAD subgroup, the invasive strategy showed a 6.3% absolute reduction in cardiovascular death or MI at 4 years, though all-cause mortality remained similar 5

This finding challenges the traditional ischemia-guided approach and suggests anatomic severity may be more important than ischemia severity for risk stratification.

Clinical Implications from Current Guidelines

When to Pursue Initial Conservative Management

The 2024 ESC and 2023 AHA/ACC guidelines now recommend initial conservative medical management for most stable coronary disease patients without left main disease or severe LV dysfunction 3, 1. This represents a paradigm shift based largely on ISCHEMIA results.

Specifically:

• Asymptomatic patients should receive OMT without routine invasive evaluation 1
• Patients with mild-to-moderate symptoms should undergo a trial of OMT first 3

When to Consider Early Invasive Strategy

Revascularization should be considered for symptom improvement when:

• Patients remain symptomatic despite optimized antianginal therapy 3
• Patients have daily, weekly, or monthly angina at baseline 1
• Objective evidence of ischemia is present 3

Revascularization for prognostic benefit remains indicated for:

• Left main disease >50% 3
• Three-vessel disease, particularly with LV dysfunction 3
• Surgically eligible patients with multivessel disease and diabetes (CABG preferred over PCI) 3

The Role of Optimal Medical Therapy

The ISCHEMIA trial underscores that contemporary OMT is highly effective at reducing events in stable coronary disease 1. A 2025 analysis showed that achieving all four GDMT goals (SBP <130 mmHg, LDL <70 mg/dL, not smoking, antiplatelet therapy) was associated with a 16% absolute reduction in CV death/MI compared to no goals at target 6.

Blood pressure control was the most impactful single goal: Each 10 mmHg lower SBP during follow-up was associated with 10% relative risk reduction in CV death/MI 6.

Common Pitfalls and Caveats

Do not extrapolate ISCHEMIA results to excluded populations: The trial specifically excluded patients most likely to benefit from revascularization (left main disease, severe LV dysfunction, refractory angina) 3, 2

Do not ignore symptom burden: While invasive management didn't reduce hard events, it provided meaningful quality-of-life benefits for symptomatic patients 3, 1

Do not abandon ischemia testing entirely: While ischemia severity didn't predict treatment benefit in ISCHEMIA, objective evidence of ischemia remains useful for confirming the diagnosis and guiding decisions in symptomatic patients 3, 1

Do not perform routine follow-up testing in stable, asymptomatic patients: Multiple trials including POST-PCI and ReACT showed no benefit and potential harm from routine surveillance testing or angiography 1

Recognize the debate about procedural MI: The reduction in spontaneous MI with invasive management was offset by periprocedural MIs, and the prognostic significance of these different MI types remains controversial 3, 4